2024
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Yan L, Bui D, Li Y, Rajeevan N, Rowneki M, Berry K, Argraves S, Huang Y, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. Clinical Infectious Diseases 2024, 79: 643-651. PMID: 38864601, DOI: 10.1093/cid/ciae202.Peer-Reviewed Original ResearchRisk quartileVeterans Health AdministrationLowest risk quartileHighest risk quartileTarget trial emulationRisk prediction modelUntreated veteransRisk of deathOlder veteransYounger veteransHealth AdministrationTrial emulationMeasure incidenceNirmatrelvir-ritonavirVeteransHospitalUntreated participantsCOVID-19QuartileRiskSevere coronavirus disease 2019ParticipantsPersonsCoronavirus disease 2019Severe COVID-19
2021
Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program
Minnier J, Rajeevan N, Gao L, Park B, Pyarajan S, Spellman P, Haskell SG, Brandt CA, Luoh SW. Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program. JCO Precision Oncology 2021, 5: 1178-1191. PMID: 34381935, PMCID: PMC8345920, DOI: 10.1200/po.20.00541.Peer-Reviewed Original ResearchConceptsBreast Cancer Risk Assessment ToolCancer Risk Assessment ToolIncident breast cancerAbsolute lifetime riskAA womenRisk assessment toolIncident casesLifetime riskBreast cancerMillion Veteran ProgramAccurate breast cancer risk assessmentProstate Cancer Cohort ConsortiumBreast cancer risk assessmentPrior BC diagnosisBreast cancer riskClinical risk modelVeteran ProgramRisk prediction modelCancer risk assessmentAssessment toolIncident BCAfrican ancestryHazard ratioProspective cohortMultiracial cohort